Publicacións en colaboración con investigadores/as de Instituto de Salud Carlos III (16)

2022

  1. Data mining analyses for precision medicine in acromegaly: a proof of concept

    Scientific Reports, Vol. 12, Núm. 1

  2. Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response

    Biomedicines, Vol. 10, Núm. 2

2021

  1. Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas

    Clinical Endocrinology, Vol. 94, Núm. 5, pp. 811-819

2020

  1. Molecular profiling for acromegaly treatment: a validation study

    Endocrine-related cancer, Vol. 27, Núm. 6, pp. 375-389

2015

  1. Hypopituitarism After Traumatic Brain Injury

    Endocrinology and Metabolism Clinics of North America, Vol. 44, Núm. 1, pp. 151-159

  2. Influence of the exon 3 deletion of GH receptor and IGF-I level at diagnosis on the efficacy and safety of treatment with somatotropin in adults with GH deficiency

    Pituitary, Vol. 18, Núm. 1, pp. 101-107

  3. Update on prognostic factors in acromegaly: Is a risk score possible?

    Pituitary, Vol. 18, Núm. 3, pp. 431-440

2013

  1. Epidemiology, mortality rate and survival in a homogeneous population of hypopituitary patients

    Clinical Endocrinology, Vol. 78, Núm. 2, pp. 278-284

  2. Metabolic syndrome associated with hyperprolactinemia: A new indication for dopamine agonist treatment?

    Endocrine

2012

  1. Subclinical hypopituitarism

    Best Practice and Research: Clinical Endocrinology and Metabolism, Vol. 26, Núm. 4, pp. 461-469

2011

  1. GH/IGF-I Axis in Exercise

    HORMONE USE AND ABUSE BY ATHLETES (SPRINGER), pp. 1-7

  2. Pituitary stalk dysgenesis-induced hypopituitarism in adult patients: Prevalence, evolution of hormone dysfunction and genetic analysis

    Neuroendocrinology, Vol. 93, Núm. 3, pp. 181-188

2010

  1. Hypopituitarism following traumatic brain injury: Determining factors for diagnosis

    Frontiers in Endocrinology, Vol. 2, Núm. AUG

  2. Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndrome

    Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 5, pp. 2147-2154

  3. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly

    Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 1, pp. 222-229

2009

  1. Pegvisomant-induced cholestatic hepatitis with jaundice in a patient with Gilbert's syndrome

    European Journal of Endocrinology, Vol. 160, Núm. 5, pp. 869-872